Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation

Web Exclusives - Leukemia

 

 

Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation

New results from the international, randomized, phase 3 clinical trial QuANTUM-R show that the targeted drug quizartinib, an oral, selective FLT3 inhibitor, significantly extended overall survival compared with chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) and the FLT3-ITD mutation, the most common FLT3 gene mutation, affecting approximately 25% of patients with AML. These results from QuANTUM-R make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.

“Single agent quizartinib is the first FLT3 inhibitor to show a significant improvement in overall survival compared to cytotoxic chemotherapy in a randomized phase 3 study of patients with relapsed/refractory AML with FLT3-ITD mutations, a very aggressive form of the disease with limited treatment options,” said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo, in a press release from the company.

Treatment options for patients with relapsed or refractory AML and the FLT3-ITD mutation are limited, and no therapy targeting the FLT3-ITD mutation has yet been approved by the US Food and Drug Administration (FDA). Patients with AML and this mutation have a poor prognosis, characterized by increased risk for relapse and death, as well as an increased risk for relapse after hematopoietic stem-cell transplant (HSCT) compared with patients who do not have this mutation.

In QuANTUM-R, 367 patients with relapsed or refractory AML and the FLT3-ITD mutation who had received standard first-line therapy, with or without HSCT, were randomized in a 2:1 ratio to quizartinib or to salvage chemotherapy. Quizartinib met the study’s primary end point, which was whether quizartinib monotherapy extended overall survival compared with salvage chemotherapy. In addition, the study results demonstrated that the safety of quizartinib was consistent with that observed at similar doses in an ongoing comprehensive development program for the drug, which includes the QuANTUM-First trial, and a variety of combination trials.

The FDA granted quizartinib an orphan drug designation for the treatment of patients with AML, as well as a fast track status for relapsed or refractory AML. Based on these new results from QuANTUM-R, Daiichi Sankyo will start the global regulatory submissions for quizartinib in the setting of AML with FLT3-ITD mutation.

Related Items
November 4, 2019 — Oncology News & Updates
Yvette Florio Lane
Web Exclusives published on November 5, 2019 in Financial Toxicity, Head and Neck Cancer, Hematologic Cancers, In the News, Leukemia
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Updates, Leukemia
Lumoxiti (Moxetumomab Pasudotox-tdfk) First CD22-Directed Cytotoxin FDA Approved for Relapsed or Refractory Hairy-Cell Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Updates, Leukemia
Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Drug Updates, FDA Updates, Leukemia
Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Updates, Leukemia
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with CLL
Wayne Kuznar
JHOP - March 2019 Vol 9, No 1 published on March 13, 2019 in Leukemia, ASH
Kymriah (Tisagenlecleucel) for Young Patients with Acute Lymphoblastic Leukemia: First FDA-Approved Gene Therapy
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Updates, Leukemia
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Updates, Leukemia
Successful Treatment of Chronic Myeloid Leukemia with Low-Dose Nilotinib
Eric Haigh, BS, Kamran Darabi, MD
Online First published on November 3, 2017 in Case Reports, Leukemia
Last modified: February 19, 2019